Translate
Spyre Therapeutics, Inc.
About
71.79USD-0.72 -0.99%
Closed • Updated at 14:46 GMT+00:00Market Cap$6.23B
Volume74.6K
Beta1.96
RSI53.27
Spyre Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 5 2026
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Apr 16 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
Apr 14 2026
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
Apr 13 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Apr 13 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Recent Videos
Spyre Therapeutics SYRE Stock 2026 Analysis – 111% YTD Return With Zero Revenue
May 04, 2026
SYRE, Spyre Therapeutics, Inc. stock prices historical data
Apr 26, 2026
Spyre Therapeutics Valuation: Mispricing a $6.9B Disruption
Apr 21, 2026
Spyre Therapeutics Prices $403M Offering at $62
Apr 15, 2026
Community Chat
Ask AI
Try asking